Literature DB >> 25975955

Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry.

Tehillah S Menes1, Mary Beth Terry, David Goldgar, Irene L Andrulis, Julia A Knight, Esther M John, Yuyan Liao, Melissa Southey, Alexander Miron, Wendy Chung, Saundra S Buys.   

Abstract

BReast CAncer genes 1 and 2 (BRCA1 and BRCA2) mutation carriers diagnosed with breast cancer are at increased risk of developing a second primary breast cancer. Data from high-risk clinics may be subject to different biases which can cause both over and underestimation of this risk. Using data from a large multi-institutional family registry we estimated the 10-year cumulative risk of second primary breast cancer including more complete testing information on family members. We prospectively followed 800 women diagnosed with breast cancer from the Breast Cancer Family Registry (BCFR) who were carriers of a BRCA1 or BRCA2 pathogenic mutation or a variant of unknown clinical significance. In order to limit survival and ascertainment bias, cases were limited to those diagnosed with a first primary breast cancer from 1994 to 2001 and enrolled in the BCFR within 3 years after their cancer diagnosis. We excluded women enrolled after being diagnosed with a second breast cancer. We calculated 10-year incidence of second primary breast cancers. The 10-year incidence of a second primary breast cancer was highest in BRCA1 mutation carriers (17 %; 95 % CI 11-25 %), with even higher estimates in those first diagnosed under the age of 40 (21 %; 95 % CI 13-34 %). Lower rates were found in BRCA2 mutation carriers (7 %; 95 % CI 3-15 %) and women with a variant of unknown clinical significance (6 %; 95 % CI 4-9 %). Whereas the cumulative 10-year incidence of second primary breast cancer is high in BRCA1 mutation carriers, the estimates in BRCA2 mutation carriers and women with variants of unknown clinical significance are similar to those reported in women with sporadic breast cancer.

Entities:  

Mesh:

Year:  2015        PMID: 25975955      PMCID: PMC4545282          DOI: 10.1007/s10549-015-3419-y

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  24 in total

Review 1.  Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation.

Authors:  Hester M Klaren; Laura J van't Veer; Flora E van Leeuwen; Matti A Rookus
Journal:  J Natl Cancer Inst       Date:  2003-07-02       Impact factor: 13.506

2.  Risk of contralateral breast cancer associated with common variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mutation carrier status.

Authors:  Jane C Figueiredo; Jennifer D Brooks; David V Conti; Jenny N Poynter; Sharon N Teraoka; Kathleen E Malone; Leslie Bernstein; Won D Lee; David J Duggan; Ashley Siniard; Patrick Concannon; Marinela Capanu; Charles F Lynch; Jørgen H Olsen; Robert W Haile; Jonine L Bernstein
Journal:  Breast Cancer Res Treat       Date:  2010-12-15       Impact factor: 4.872

3.  Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients.

Authors:  Madeleine M A Tilanus-Linthorst; Karina C M Bartels; Celina Alves; Bonnie Bakri; Ellen Crepin; Ans van den Ouweland; Jan G M Klijn; Hanne Meijers-Heijboer; Cecile T M Brekelmans
Journal:  Breast Cancer Res Treat       Date:  2006-01       Impact factor: 4.872

4.  Classification of missense substitutions in the BRCA genes: a database dedicated to Ex-UVs.

Authors:  Maxime P Vallée; Tiana C Francy; Megan K Judkins; Davit Babikyan; Fabienne Lesueur; Amanda Gammon; David E Goldgar; Fergus J Couch; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2011-11-03       Impact factor: 4.878

5.  Does Immediate Breast Reconstruction after Mastectomy affect the Initiation of Adjuvant Chemotherapy?

Authors:  Jeonghui Lee; Se Kyung Lee; Sangmin Kim; Min Young Koo; Min-Young Choi; Soo Youn Bae; Dong Hui Cho; Jiyoung Kim; Seung Pil Jung; Jun-Ho Choe; Jung-Han Kim; Jee Soo Kim; Jeong Eon Lee; Jung-Hyun Yang; Seok Jin Nam
Journal:  J Breast Cancer       Date:  2011-12-27       Impact factor: 3.588

6.  Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly Metcalfe; Henry T Lynch; Parviz Ghadirian; Nadine Tung; Ivo Olivotto; Ellen Warner; Olufunmilayo I Olopade; Andrea Eisen; Barbara Weber; Jane McLennan; Ping Sun; William D Foulkes; Steven A Narod
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

7.  Risk of second primary cancer in the contralateral breast in women treated for early-stage breast cancer: a population-based study.

Authors:  Xiang Gao; Susan G Fisher; Bahman Emami
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-15       Impact factor: 7.038

8.  High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.

Authors:  Katarina Shahedi; Monica Emanuelsson; Fredrik Wiklund; Henrik Gronberg
Journal:  Cancer       Date:  2006-03-15       Impact factor: 6.860

9.  Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.

Authors:  Kelly-Anne Phillips; Roger L Milne; Matti A Rookus; Mary B Daly; Antonis C Antoniou; Susan Peock; Debra Frost; Douglas F Easton; Steve Ellis; Michael L Friedlander; Saundra S Buys; Nadine Andrieu; Catherine Noguès; Dominique Stoppa-Lyonnet; Valérie Bonadona; Pascal Pujol; Sue Anne McLachlan; Esther M John; Maartje J Hooning; Caroline Seynaeve; Rob A E M Tollenaar; David E Goldgar; Mary Beth Terry; Trinidad Caldes; Prue C Weideman; Irene L Andrulis; Christian F Singer; Kate Birch; Jacques Simard; Melissa C Southey; Håkan L Olsson; Anna Jakubowska; Edith Olah; Anne-Marie Gerdes; Lenka Foretova; John L Hopper
Journal:  J Clin Oncol       Date:  2013-08-05       Impact factor: 44.544

Review 10.  Association between delayed initiation of adjuvant CMF or anthracycline-based chemotherapy and survival in breast cancer: a systematic review and meta-analysis.

Authors:  Ke-Da Yu; Sheng Huang; Jia-Xin Zhang; Guang-Yu Liu; Zhi-Ming Shao
Journal:  BMC Cancer       Date:  2013-05-16       Impact factor: 4.430

View more
  7 in total

1.  Genetic Risk of Second Primary Cancer in Breast Cancer Survivors: The Multiethnic Cohort Study.

Authors:  Fei Chen; Sungshim L Park; Lynne R Wilkens; Peggy Wan; Steven N Hart; Chunling Hu; Siddhartha Yadav; Fergus J Couch; David V Conti; Adam J de Smith; Christopher A Haiman
Journal:  Cancer Res       Date:  2022-09-16       Impact factor: 13.312

2.  Strategies to enhance identification of hereditary breast cancer gene carriers.

Authors:  Sonya Reid; Lucy B Spalluto; Tuya Pal
Journal:  Expert Rev Mol Diagn       Date:  2020-09-11       Impact factor: 5.225

3.  Disparities in Genetic Testing and Care among Black women with Hereditary Breast Cancer.

Authors:  Sonya Reid; Sydney Cadiz; Tuya Pal
Journal:  Curr Breast Cancer Rep       Date:  2020-05-19

4.  Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report.

Authors:  Thomas Waddington; Isa Mambetsariev; Rebecca Pharaon; Jeremy Fricke; Angel Ray Baroz; Hannah Romo; Bassam Ghanem; Stacy Gray; Ravi Salgia
Journal:  Clin Lung Cancer       Date:  2021-01-27       Impact factor: 4.840

5.  Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.

Authors:  Jan Drooger; Delal Akdeniz; Jean-Philippe Pignol; Linetta B Koppert; Danielle McCool; Caroline M Seynaeve; Maartje J Hooning; Agnes Jager
Journal:  Breast Cancer Res Treat       Date:  2015-11       Impact factor: 4.872

6.  Tumor characteristics and prognosis in familial breast cancer.

Authors:  G Arpino; M Pensabene; C Condello; R Ruocco; I Cerillo; R Lauria; V Forestieri; M Giuliano; C De Angelis; M Montella; A Crispo; S De Placido
Journal:  BMC Cancer       Date:  2016-11-29       Impact factor: 4.430

7.  Regulation of Lipocalin-2 oncogene and its impact on gene polymorphisms on breast cancer patients in Jeddah, Saudi Arabia.

Authors:  Sabah Linjawi; Zuhoor AlGaithy; Samar Sindi; Norah Hamdi; Ayman Linjawi; Mona Alharbi
Journal:  Saudi Med J       Date:  2018-06       Impact factor: 1.484

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.